Jan J Molenaar

List of Publications by Year
in descending order

42 papers	4,586 citations	361413 20 h-index	276875 41 g-index
43 all docs	43 docs citations	43 times ranked	7642 citing authors

#	Article	IF	Citations
1	Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies. European Journal of Cancer, 2022, 162, 107-117.	2.8	11
2	High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling. Biomedicines, 2022, 10, 638.	3.2	4
3	Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics. Cancer Science, 2022, 113, 2167-2178.	3.9	8
4	Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours. European Journal of Cancer, 2022, 170, 196-208.	2.8	4
5	Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses. European Journal of Cancer, 2021, 142, 1-9.	2.8	11
6	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. Science Advances, 2021, 7, .	10.3	78
7	Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, .	0.6	1
8	International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer. Molecular Cancer Therapeutics, 2021, 20, 1462-1468.	4.1	14
9	Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Reports, 2021, 36, 109568.	6.4	25
10	The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development. Cancers, 2021, 13, 4324.	3.7	22
11	Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies. Journal of Personalized Medicine, 2021, 11, 869.	2.5	11
12	Simple, fast and efficient iTOP-mediated delivery of CRISPR/Cas9 RNP in difficult-to-transduce human cells including primary T cells. Journal of Biotechnology, 2021, 338, 71-80.	3.8	14
13	Î±Î²-T Cells Engineered to Express Î³Î´-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression. Journal of Personalized Medicine, 2021, 11, 923.	2.5	5
14	Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	16
15	Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. Pediatric Blood and Cancer, 2020, 67, e28061.	1.5	21
16	Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma. Scientific Reports, 2020, 10, 17667.	3.3	20
17	Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. European Journal of Cancer, 2020, 130, 168-181.	2.8	7
18	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 2020, 11, 1310.	12.8	183

#	Article	IF	Citations
19	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
20	Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. European Journal of Cancer, 2017, 75, 63-72.	2.8	23
21	p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clinical Cancer Research, 2017, 23, 6629-6639.	7.0	23
22	Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nature Genetics, 2017, 49, 1261-1266.	21.4	362
23	Î³-secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. Oncotarget, 2016, 7, 62799-62813.	1.8	12
24	DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. PLoS ONE, 2015, 10, e0145744.	2.5	22
25	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research, 2015, 21, 5100-5109.	7.0	49
26	MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma. Cancer Letters, 2015, 366, 123-132.	7.2	51
27	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
28	TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nature Genetics, 2015, 47, 1411-1414.	21.4	313
29	Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica, 2015, 100, e132-e136.	3.5	29
30	Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma. Journal of Molecular Diagnostics, 2015, 17, 43-52.	2.8	19
31	Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget, 2015, 6, 18558-18576.	1.8	26
32	Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget, 2015, 6, 35770-35781.	1.8	37
33	Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. European Journal of Cancer, 2014, 50, 628-637.	2.8	57
34	Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 2014, 92, 144-148.	2.8	2
35	Towards Personalized Therapy in Pediatric Acute Lymphoblastic Leukemia; Ras Mutations and Prednisolone Resistance. Blood, 2014, 124, 372-372.	1.4	0
36	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature Genetics, 2012, 44, 1199-1206.	21.4	336

#	Article	IF	Citations
37	Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature, 2012, 483, 589-593.	27.8	775
38	Copy number defects of G1â€Cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes and Cancer, 2012, 51, 10-19.	2.8	57
39	Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12968-12973.	7.1	147
40	Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma. Cancer Research, 2008, 68, 2599-2609.	0.9	141
41	Pulmonary interstitial glycogenosis in identical twins. Pediatric Pulmonology, 2005, 40, 362-366.	2.0	51
42	Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes and Cancer, 2003, 36, 242-249.	2.8	79